Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
November 28, 2014, 01:12:15 AM

Login with username, password and session length


Members
  • Total Members: 24072
  • Latest: Esfesf
Stats
  • Total Posts: 647675
  • Total Topics: 49358
  • Online Today: 155
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 4
Guests: 127
Total: 131

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: VIRxSYS (VRX496) News  (Read 9405 times)

0 Members and 1 Guest are viewing this topic.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
VIRxSYS (VRX496) News
« on: January 24, 2009, 06:54:25 PM »
WHAT:   

        VIRxSYS to present data on its first clinical trial using
        lentiviral vectors in a presentation entitled Findings from
        Phase I/II and decisions regarding next step. The presentation
        will address the following:
        -- Successful delivery of a 937 base antisense sequence to HIV
        envelope
        -- Cumulative data on patient safety monitoring
        -- Coordination between manufacturing and clinical through the phases
        -- The next clinical trial: Phase IIb or phase III? Discussions with
        the regulator
        -- Defining the optimum patient population
        -- Re-imbursement models
WHY:   

        VIRxSYS' novel lentiviral vector platform and ongoing clinical
        trials show great promise in a safe and effective treatment for
        people with HIV. The company's gene therapy treatment, VRX496, can
        be replicated on a larger scale and is encouraging as a means to
        suppress and block HIV. To date, VRX496 has been administered in
        61 patients, representing an accumulative patient safety
        monitoring of 142 patient years. VRX496 is different from previous
        gene therapies because it uses a lentiviral vector derived from
        HIV-1 itself.

WHO:   

        VIRxSYS EVP of scientific and clinical affairs, Gerard J.
        McGarrity, PhD. Dr. McGarrity has over 20 years experience in
        the biotechnology industry and has authored more than 160
        scientific publications.

WHERE: 

        The 2009 Phaciliate Cell & Gene Therapy Forum, The Grand Hyatt
        Hotel, Washington, D.C.

WHEN:   
        Monday, January 26, 2009. VIRxSYS presentation will be held in Focus
        Session 2 at 2:55 p.m.


SOURCE: VIRxSYS
« Last Edit: January 25, 2009, 03:33:26 PM by John2038 »

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
Re: VIRxSYS (VRX496) News
« Reply #1 on: January 27, 2009, 04:16:15 PM »
VRX496 Update, Novel HIV Gene Therapy
 
 
VIRxSYS Announces Completion of Phase I Study of VRX496, Novel HIV ...
 
The viral vector plus antisense is called VRX496. The antisense genetic medicine blocks HIV replication in CD4 T cells, which would otherwise be destroyed ...
www.natap.org/2005/newsUpdates/050505-01.htm
 
HIV gene therapy study 'shows promise'
The researchers are now recruiting for a second trial of the treatment - dubbed VRX496. This time it will be tested on patients whose HIV load is already ...
www.natap.org/2006/newsUpdates/110906_03.htm




















Source

Offline Alefou

  • Member
  • Posts: 62
Re: VIRxSYS (VRX496) News
« Reply #2 on: April 06, 2009, 08:51:28 AM »
I was reading this ting and I think it's very encouraging. When I look on the clinical trial website, the trial is was scheduled to end on March 2009 ....

Let's wait for the results  ::)
12/16/2008 : Probable infection
12/26/2008 : ARS (Flu for one week)
01/15/2009 : HIV rapid test neg
01/28/2009 : Rapid test poz
01/31/2009 : Two EIA Poz
02/03/2009 : WB pos, CD4 : 832 (32%), VL : 116k copies/ml
03/08/2009 : CD4 : 836 (38%), VL : 104k

Offline xman

  • Member
  • Posts: 288
Re: VIRxSYS (VRX496) News
« Reply #3 on: July 31, 2009, 02:46:16 PM »
There's a phase I/II trial ending now. I hope we will have some results very soon! This one of the most promising trials since it is in advanced phases.

http://clinicaltrials.gov/ct2/show/NCT00295477?term=VRX496&rank=2

Maybe they're waiting to finish all trials before releasing any results.
« Last Edit: July 31, 2009, 02:55:55 PM by xman »
sign the petition launched by the aids policy project addressed to the nih aimed to increase the money needed to find the cure:

http://www.aidspolicyproject.org/petition_for_the_nih

we can make a difference and we need to fight. please support them! it doesn't cost you anything. they need it now more than ever!

Offline riptide

  • Member
  • Posts: 7
Re: VIRxSYS (VRX496) News
« Reply #4 on: July 31, 2009, 07:13:35 PM »
 I read somewhere on the net and of course I cant find the link.... VIRxSYS was moving into a phase II roll over study to follow up with some of the patients that received treatment in the I/II study. It didnt mention to many details from what I remember reading. Maybe the one XMAN is talking about. ???

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: VIRxSYS (VRX496) News
« Reply #5 on: August 04, 2009, 12:50:59 AM »
At CROI 2009, which was in February 2009, they presented data from the trial and said it was "ongoing," so I'm hoping more data will be presented after the official completion of the trial , which was July 2009.

Penn Medicine presents HIV gene therapy trial data at CROI 2009

PHILADELPHIA – Researchers from Penn Medicine announced today the results from an ongoing Phase I/II
open label clinical trial of VRX496 at the 16th Conference on Retroviruses and Opportunistic Infections
(CROI) in Montreal. VRX496 is a gene therapy product being investigated for the treatment of HIV
infection. During the trial VRX496 was administered to twelve subjects prior to a controlled scheduled
treatment interruption (STI) from their current antiretroviral therapy.

"We continue to see the strong safety and tolerability profile that VRX496 demonstrated in the Phase I
clinical trials," said Carl June, MD, Professor of Pathology and Laboratory Medicine at Penn. "What we are
seeing now is the potential to generate a sustained immune system response in patients who have stopped taking their anti-retroviral regimens.
Potentially this could lead to a shift in the treatment of HIV infection from trying to eradicate the HIV virus; which requires a daily regimen of pills and is ultimately a short-term solution because of the ability of HIV to mutate, to an approach where the body acquires immunity to HIV infection through a series of infusions."

The presentation "Safety, Antiviral Effect and Quantitative Measurement of Modified CD4+ T Cells
Trafficking to Gut Associated Lymphoid Tissue in a Phase I/II Open-label Clinical Trial Evaluative Multiple
Infusions of Lentiviral Vector-modified CD4+ T Cells Expressing Long env Antisense" was made by Pablo
Tebas, MD, at CROI 2009 on February 10th at 10 AM. Tebas is an Assistant Professor of Medicine at the
University of Pennsylvania School of Medicine.

"Multiple infusions of lentiviral-vector-modified cells appear to increase CD4+ counts and may decrease
viral load set point. We appear to have successfully reconstituted the CD4+ cell population in the gut with
VRX496 modified cells, which is a major site of HIV replication and suggests that the modified cells are
going where they need to go," said Pablo Tebas MD, Assistant Professor, University of Pennsylvania School
of Medicine. "The multiple infusions of lentiviral vector VRX496 with long antisense RNA appear to be safe,
and no serious adverse events were noted."

The results presented at CROI are from an ongoing Phase I/II trial of HIV-1 infected subjects fully
suppressed on Anti-Retroviral Treatments (ART). Patients received up to six infusions over 14 weeks. At
week 18 subjects interrupted their ART. Patients were monitored for adverse events, viral load, CD4+ T
cell count, vector-derived replication competent lentivirus (RCL) and immunogenicity, vector DNA
integration patterns, and TCR diversity.


LINK:

http://www.virxsys.com/media/.download_gallery/February%2010%20%202009.pdf
« Last Edit: August 04, 2009, 01:59:15 PM by Inchlingblue »

Offline tommy246

  • Standard
  • Member
  • Posts: 435
Re: VIRxSYS (VRX496) News
« Reply #6 on: August 04, 2009, 12:44:06 PM »
That sounds great news if successful when could this become available
jan 06 neg
dec 08 pos cd4 505 ,16%, 1,500vl
april 09 cd4 635 ,16%,60,000
july 09 ,cd4 545,17%,80,000
aug 09,hosptal 18days pneumonia cd190,225,000,15%
1 week later cd4 415 20%
nov 09 cd4 591 ,vl 59,000,14%,started atripla
dec 09  cd4 787, vl 266, 16%
march 2010  cd4 720 vl non detectable -20  20%
june 2010  cd4  680, 21%, ND

Offline xman

  • Member
  • Posts: 288
Re: VIRxSYS (VRX496) News
« Reply #7 on: August 04, 2009, 01:12:51 PM »
If they start phase III trials in 2010 I guess 5-7 years and we will have it on the market. I guess the trials are long due to safety issues since gene therapy is a new approach and we know nothing about possible long term effects.
sign the petition launched by the aids policy project addressed to the nih aimed to increase the money needed to find the cure:

http://www.aidspolicyproject.org/petition_for_the_nih

we can make a difference and we need to fight. please support them! it doesn't cost you anything. they need it now more than ever!

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: VIRxSYS (VRX496) News
« Reply #8 on: August 09, 2009, 03:22:01 PM »
Here's an interesting Q&A about VRX496 from thebody;com:

LINK:

http://www.thebody.com/Forums/AIDS/Labs/Current/Q203264.html

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: VIRxSYS (VRX496) News
« Reply #9 on: February 18, 2010, 11:38:26 PM »
VIRxSYS Announces at CROI Promising Results from Its HIV Vaccine Study

GAITHERSBURG, Md. - (Business Wire) VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA. The study has demonstrated that the VIRXSYS vaccine, VRX1023, is capable of achieving significant control of viral load over the course of four months following a challenge with a highly pathogenic simian immunodeficiency virus (SIV), a virus found in non-human primates and similar to HIV. In addition, monkeys vaccinated with VRX1023 demonstrated an improved immune response. VIRxSYS is currently preparing an Investigational New Drug Application for the therapeutic use of their HIV vaccine candidate in HIV infected patients.


Continued . . .

LINK:

http://www.earthtimes.org/articles/show/virxsys-announces-at-croi-promising-results-from-its-hiv-vaccine-study,1171120.shtml

Penn researchers present Phase II HIV gene therapy trial data at CROI 2010

LINK:

http://www.eurekalert.org/pub_releases/2010-02/uops-prp021710.php

This article clearly explains the difference between VRX496 and VRX1023, both from VIRxSYS:

U.S. company Virxsys says using AIDS to fight AIDS

LINK:

http://www.reuters.com/article/idUSTRE61I00820100219
 
« Last Edit: February 19, 2010, 12:25:51 AM by Inchlingblue »

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
Re: VIRxSYS (VRX496) News
« Reply #10 on: February 20, 2010, 06:16:54 PM »
VIRxSYS seems promising accordingly to the presentation they have made at the CROI 2010.

You will find many articles on the net about what has been said.
Among others:

"We said 'let's use HIV against itself', and that's what we're doing", New Scientist quoted Gary McGarrity, VIRxSYS's vice president of scientific and clinical affairs, as saying.

Describing how they vaccinated monkeys, and then six months later injected them with SIV, VIRxSYS researchers said, “Within weeks of receiving the injection of SIV, concentrations of the virus had fallen by at least 95 per cent in those treated. After a year, when the trial ended, these concentrations remained low, whereas untreated monkeys became progressively sicker as their immune systems were depleted by the virus”.


You may want to read that also:

“The results from this trial are very impressive and I believe could provide real excitement in the world of HIV vaccines.

Something is happening I guess ...





Offline Hellraiser

  • Member
  • Posts: 4,140
  • Semi-misanthropic
Re: VIRxSYS (VRX496) News
« Reply #11 on: February 20, 2010, 06:39:16 PM »
The next step is taking hiv- people, giving them the vaccine and then exposiing them to the virus?

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: VIRxSYS (VRX496) News
« Reply #12 on: February 20, 2010, 07:22:33 PM »
Keep in mind they reported on findings of two different products, VRX496 and VRX1023. Both were promising but they are each very different from each other. Explained in the link in my previous post.

Offline John2038

  • Member
  • Posts: 1,529
  • Happiness is a journey, not a destination.
    • HIV Research News (Twitter)
Re: VIRxSYS (VRX496) News
« Reply #13 on: February 20, 2010, 08:13:42 PM »
Hellraiser

About the VRX1023, the company is planning to apply for approval to perform human trials.

VIRxSYS says such trials would initially be only in people who already carry the virus, rather than in healthy people at risk of infection. This will certainly make for a less controversial trial, as it would avoid any chance of the vaccine going "live" and infecting people who didn't have HIV to start with.

http://www.newscientist.com/article/dn18551-fight-hiv-with-hiv-safe-virus-proposed-as-vaccine.html

About the VRX496, human trials have already been made and are still on-going.

Offline tommy246

  • Standard
  • Member
  • Posts: 435
Re: VIRxSYS (VRX496) News
« Reply #14 on: February 21, 2010, 06:26:03 AM »
Thats very intresting and good news john sounds like there happy with the results with the monkeys when will the human trialls be complete any ideas ?
Also how often would these vaccines be taken .
jan 06 neg
dec 08 pos cd4 505 ,16%, 1,500vl
april 09 cd4 635 ,16%,60,000
july 09 ,cd4 545,17%,80,000
aug 09,hosptal 18days pneumonia cd190,225,000,15%
1 week later cd4 415 20%
nov 09 cd4 591 ,vl 59,000,14%,started atripla
dec 09  cd4 787, vl 266, 16%
march 2010  cd4 720 vl non detectable -20  20%
june 2010  cd4  680, 21%, ND

Offline sensual1973

  • Member
  • Posts: 195
Re: VIRxSYS (VRX496) News
« Reply #15 on: February 21, 2010, 07:27:35 AM »
.
« Last Edit: February 21, 2010, 08:14:33 AM by sensual1973 »
God grant me the serenity to accept the things i can not change.

Offline hahaha

  • Member
  • Posts: 123
Re: VIRxSYS (VRX496) News
« Reply #16 on: February 21, 2010, 09:17:18 PM »
Does Virxsys give out any charts, numbers, diagram in CROI 2010 for reference purpose?
Am curious about how "good" they are after injection, and how long it last.
Aug 9, 2006 Get infected in Japan #$%^*
Oct 2006 CD4 239
Nov 2006 CD4 299 VL 60,000
Dec 1, Sustiva, Ziagan and 3TC
Jan 07, CD4 400

Offline Inchlingblue

  • Member
  • Posts: 3,119
  • Chad Ochocinco PETA Ad
Re: VIRxSYS (VRX496) News
« Reply #17 on: May 24, 2010, 03:04:00 PM »
VIRxSYS Presents Results From Multiple Studies At The 13th ASGCT Annual Meeting

LINK:

http://www.medicalnewstoday.com/articles/189685.php

Offline BlackLion

  • Member
  • Posts: 7
Re: VIRxSYS (VRX496) News
« Reply #18 on: May 25, 2010, 02:59:10 AM »
"In accordance with FDA guidelines, all subjects will continue to be monitored for safety for up to 15 years"

Anyone can explain that? we must wait 15 years in case that VRX496 succeed in treating infeted people?

Offline Hellraiser

  • Member
  • Posts: 4,140
  • Semi-misanthropic
Re: VIRxSYS (VRX496) News
« Reply #19 on: May 25, 2010, 09:40:16 AM »
"In accordance with FDA guidelines, all subjects will continue to be monitored for safety for up to 15 years"

Anyone can explain that? we must wait 15 years in case that VRX496 succeed in treating infeted people?

Pretty sure that means after they've been released for public consumption they will be monitored for 15 years.  I could be wrong about that.

Offline BlackLion

  • Member
  • Posts: 7
Re: VIRxSYS (VRX496) News
« Reply #20 on: May 26, 2010, 04:53:45 AM »
Thanks, I hope that I can use them soon so that I would be monitored for 15 years  ;D

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.